Davita Inc (NYSE:DVA) saw some unusual options trading activity on Tuesday. Traders purchased 6,229 call options on the company. This represents an increase of 610% compared to the typical volume of 877 call options.
In other Davita news, Director Pamela M. Arway sold 599 shares of the company’s stock in a transaction dated Friday, May 22nd. The shares were sold at an average price of $78.90, for a total value of $47,261.10. Following the completion of the transaction, the director now owns 19,239 shares in the company, valued at $1,517,957.10. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Charles Berg sold 357 shares of the company’s stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $87.53, for a total transaction of $31,248.21. Following the completion of the transaction, the director now owns 15,666 shares of the company’s stock, valued at approximately $1,371,244.98. The disclosure for this sale can be found here. Insiders have sold 12,109 shares of company stock valued at $989,903 over the last 90 days. 1.10% of the stock is currently owned by insiders.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Northwestern Mutual Investment Management Company LLC boosted its stake in Davita by 33.5% during the first quarter. Northwestern Mutual Investment Management Company LLC now owns 4,650 shares of the company’s stock worth $354,000 after buying an additional 1,166 shares during the last quarter. Cipher Capital LP boosted its stake in Davita by 10.0% during the fourth quarter. Cipher Capital LP now owns 7,017 shares of the company’s stock worth $527,000 after buying an additional 636 shares during the last quarter. Victory Capital Management Inc. boosted its stake in Davita by 4,010.6% during the first quarter. Victory Capital Management Inc. now owns 44,600 shares of the company’s stock worth $3,392,000 after buying an additional 43,515 shares during the last quarter. Hartford Investment Management Co. boosted its stake in Davita by 3.3% during the first quarter. Hartford Investment Management Co. now owns 9,807 shares of the company’s stock worth $746,000 after buying an additional 312 shares during the last quarter. Finally, Alliancebernstein L.P. boosted its stake in Davita by 2.0% during the first quarter. Alliancebernstein L.P. now owns 167,833 shares of the company’s stock worth $12,765,000 after buying an additional 3,246 shares during the last quarter. 91.52% of the stock is currently owned by institutional investors.
Shares of DVA traded up $1.63 during mid-day trading on Tuesday, hitting $78.84. 27,894 shares of the company were exchanged, compared to its average volume of 1,303,565. Davita has a 1-year low of $50.68 and a 1-year high of $90.15. The company has a debt-to-equity ratio of 5.24, a quick ratio of 1.77 and a current ratio of 1.81. The company has a 50 day moving average of $79.92 and a 200-day moving average of $77.77. The stock has a market cap of $9.42 billion, a price-to-earnings ratio of 12.35, a price-to-earnings-growth ratio of 1.35 and a beta of 1.22.
Davita (NYSE:DVA) last released its earnings results on Tuesday, May 5th. The company reported $1.83 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.47 by $0.36. The business had revenue of $2.84 billion for the quarter, compared to analyst estimates of $2.84 billion. Davita had a net margin of 7.85% and a return on equity of 32.45%. The business’s revenue was up 3.6% on a year-over-year basis. During the same period last year, the company posted $0.91 EPS. Research analysts anticipate that Davita will post 6.13 earnings per share for the current fiscal year.
A number of research analysts have weighed in on the stock. SunTrust Banks upped their price objective on shares of Davita from $82.00 to $90.00 and gave the stock a “hold” rating in a research report on Wednesday, May 6th. Royal Bank of Canada reiterated a “hold” rating and issued a $75.00 price objective on shares of Davita in a research report on Monday, April 20th. Zacks Investment Research upgraded shares of Davita from a “hold” rating to a “buy” rating and set a $89.00 price objective for the company in a research report on Wednesday, June 10th. Finally, ValuEngine downgraded shares of Davita from a “hold” rating to a “sell” rating in a research report on Friday, May 1st. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and three have issued a buy rating to the company’s stock. Davita currently has a consensus rating of “Hold” and a consensus target price of $71.38.
Davita Company Profile
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Recommended Story: What Are Cryptocurrencies?
Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.